c-Met Inhibitors
2 drugsAbout c-Met
c-Met, also known as hepatocyte growth factor receptor (HGFR), is a receptor tyrosine kinase crucial for cell growth, survival, and motility. As a key signaling protein, it plays a role in tumor progression and metastasis.
c-Met is a target for drug development, particularly in oncology, but there is currently no genetic evidence directly linking c-Met to specific diseases. Its involvement in tumor progression has made it a focus for therapeutic intervention.
Two FDA-approved drugs target c-Met: XALKORI and EMRELIS. These include one small molecule and one antibody-drug conjugate (ADC), both for oncology indications.
Top c-Met Drugs
Two companies, PF PRISM CV and AbbVie, have approved drugs targeting c-Met.
Low market concentration suggests relatively low barriers to entry for new competitors.
c-Met Drug Modality Landscape
Modalities
Routes of Administration
c-Met is druggable by both biologics (1) and small molecules (1), indicating broad therapeutic accessibility.
The absence of other modalities represents a whitespace opportunity for innovation.
📈 Modality Evolution
Small molecules pioneered c-Met targeting (2011), with adcs entering more recently (2025).
c-Met Clinical Trials 92 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on c-Met. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 34 | 25 | 6 | 3 | 81% |
| Phase 2 | 38 | 14 | 7 | 17 | 67% |
| Phase 3 | 17 | 5 | 1 | 11 | 83% |
| Phase 4 | 3 | 0 | 2 | 1 | 0% |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
3 Phase 3 trials testing approved c-Met drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting c-Met. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
c-Met Drug Approval Timeline (2011 - 2025)
The first drug was approved in 2011, and the most recent in 2025, spanning 15 years.
The recent approval suggests renewed interest and potential for further development.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 44 (11 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on c-Met. A trial counts if an approved drug acting on c-Met is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.